David Risinger
David Risinger is an analyst at Leerink Partners, focusing on the healthcare sector. He provided commentary on Johnson & Johnson's financial performance, noting the company's cautious approach in maintaining its earnings forecast amidst stock market volatility and the looming threat of tariffs. Risinger's analysis highlights the resilience of J&J in navigating a challenging economic landscape.
Not in the pool (under ¢1).
Recent news mentions
David Risinger, an analyst with Leerink Partners, wrote in a note to clients that the tariffs should not affect many larger pharmaceutical companies because they have construction projects underway.
Pharmaceutical tariffs: A 100% tariff on some imported drugs is coming October 1, Trump says
United States· 2025-09-26
David Risinger stated that Lilly could 'flood the world with orforglipron'.
Na trg vstopa tableta za hujšanje, ki naj bi postala vodilna na trgu
Slovenia· 2025-08-25
David Risinger, a Leerink analyst, wrote that J&J’s decision not to slash its forecast is a welcome relief in the wake of recent stock market turmoil.
Johnson & Johnson warns pharma tariffs could cause drug shortages – The Irish Times
Ireland· 2025-04-15
